A pilot double-blind study of sodium-magnesium EDTA in peripheral vascular disease.

What Was Tested

Researchers studied Edetic Acid in this randomized controlled trial publication.

Ten male patients with peripheral vascular disease, Type 2 (LaFontaine), were randomly assigned in a double-blind study to receive either Na2 ethylene diamine tetra acetic acid (EDTA) plus MgSO4, B complex, and vitamin C, or a placebo of MgSO4, B complex, and vitamin C in Ringer's lactate solution.

A total of 20 intravenous infusions were planned for administration to each patient.

Who Took Part

The abstract describes 10 patients taking part.

PubMed indexes the participants as adults and middle-aged adults, men only.

How the Study Was Run

In design terms this was a randomized, double-blind, single-blind, placebo-controlled and pilot study.

Random assignment meant chance, not the researchers, decided who got Edetic Acid and who got the comparison, which limits bias.

As a double-blind Edetic Acid study, the assignments were hidden from both participants and investigators until the end.

Only one side, usually the patients, was kept unaware of whether Edetic Acid was given.

Some patients received a placebo instead of Edetic Acid, giving a reference point.

What Was Measured

The subject headings attached to it are Clinical Trials as Topic, Edetic Acid, Pilot Projects and Vascular Diseases.

What This Means in Plain Language

The paper is a randomized, double-blind and single-blind study of Edetic Acid in 10 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1990 (Journal of the National Medical Association), a journal based in United States.

More context: all human trials.